• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Timothy Wright - Articles and news items

Novartis logo

New data show Novartis’ Gilenya® reduced brain volume loss by one third and confirm brain volume loss link with disability in MS patients

Industry news / 4 October 2013 / Novartis

“The data presented today are very encouraging because they are from studies that took place over four years…”

Novartis logo

Novartis marks 30 year anniversary in transplantation and reinforces continued commitment to organ recipients at ESOT congress

Industry news, News / 4 September 2013 / Novartis

Novartis reaffirms continued innovation in transplant during anniversary year of breakthrough therapy, ciclosporin…

Novartis logo

Novartis receives EU approval for Ilaris® in active Systemic Juvenile Idiopathic Arthritis, a serious form of childhood arthritis

Industry news, News / 3 September 2013 / Novartis

Ilaris® is the first interleukin-1 beta (IL-1 beta) inhibitor for the treatment of Systemic Juvenile Idiopathic Arthritis (SJIA) and is the only treatment approved specifically for SJIA that is given as a monthly subcutaneous injection[1]…

Novartis logo

Novartis receives FDA breakthrough therapy designation for BYM338 (bimagrumab) for sporadic inclusion body myositis (sIBM)

Industry news, News / 20 August 2013 / Novartis

Novartis announced that the US FDA has granted breakthrough therapy designation to BYM338 for sporadic inclusion body myositis (sIBM)…

Novartis logo

Switching to Novartis drug Gilenya from standard interferon shown to improve long-term outcomes for patients with MS

Industry news, News / 10 June 2013 / Novartis

Two new analyses from the Phase III TRANSFORMS study presented…

Novartis logo
Novartis logo
Novartis logo
Novartis logo
Novartis logo

Novartis appoints Timothy Wright, M.D. as Global Head, Development, Novartis Pharmaceuticals

Industry news, News / 9 November 2011 / Novartis

Novartis announced the appointment of Timothy Wright…